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Abstract
The dose of vitamin D in the management of osteoporosis
should be no less than 700–800 IU per day. An optimal
dose of vitamin D should raise serum concentrations of 25
(OH)D to the desirable range of at least 75 nmol/l. Higher
intermittent oral doses of vitamin D may overcome low
adherence. Vitamin D supplementation in the management
of osteoporosis holds a significant public health potential
because of its low cost, excellent tolerability, and combined
musculo-skeletal benefits. Fall and fracture prevention with
vitamin D is especially appealing in the treatment of older
individuals at risk for fall-related fractures. However, bone
density, strength, and function benefits with vitamin D
include active and inactive subgroups of community-
dwelling older men and women. Based on a recent expert
panel and supportive evidence presented in this review,
serum concentrations of at least 75 nmol/l 25(OH)D will be
referred to as desirable. Today, desirable serum 25(OH)D
levels of at least 75 nmol/l may only be reached in about
one third of US older individuals and even fewer European
older individuals. Two main factors discussed in this review
may help public health efforts to ensure desirable vitamin D
levels for fall and fracture prevention, including (1) a
sufficient dose of vitamin D and (2) improved adherence to
supplementation.
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Desirable 25-hydroxyvitamin D levels for fall
and fracture prevention
In a recent quasi-consensus of vitamin D experts (five out
of six), a threshold of 75 nmol/l was proposed as the serum
25(OH)D concentration at which older men and women
will be at a lower risk of fracture [1]. This is supported by a
recent meta-analysis of primary prevention high-quality
trials (n=9,829) where 700–800 IU of vitamin D per day
(with or without calcium) could prevent about one fourth of
all hip and non-vertebral fractures in both ambulatory and
institutionalized older persons [2], while 400 IU did not
reduce fracture risk. A total of 700–800 IU vitamin D per
day reduced the relative risk (RR) of hip fracture by 26%
[pooled RR=0.74; 95% CI (0.61, 0.88)] and any non-
vertebral fracture by 23% (pooled RR=0.77; 95% CI [0.68,
0.87]) compared to calcium or placebo. Notably, across all
trials there was a statistically significant positive association
between higher 25(OH)D levels achieved in the treatment
group and anti-fracture efficacy. Anti-fracture efficacy was
observed with achieved mean serum 25(OH)D levels of at
least 74 nmol/l, and this threshold was only reached in
trials that provided 700–800 IU vitamin D (cholecalciferol)
per day. Whether fracture efficacy would be even higher
with higher doses of vitamin D moving a majority of
individuals into the desirable range of 75 nmol/l 25(OH)D
and above is likely, but has not been investigated. However,
indirect support is provided by data from the large
population-based US survey NHANES III (National Health
and Nutrition Examination Survey), where both hip bone
density [3] and lower extremity function improved contin-
uously with higher serum 25(OH)D concentrations [4], and
serum concentrations between 75 to 100 nmol/l appeared to
be most advantageous for both outcomes in individuals age
60 and older.
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The effect of vitamin D on the risk of falling in older
persons has been addressed in a recent meta-analysis [5].
Based on five RCTs (n=1,237), vitamin D reduced the risk
of falling by 22% [pooled corrected OR=0.78; 95% CI
(0.64, 0.92)] compared to calcium or placebo [6–10].
Subgroup analyses suggested that 400 IU of vitamin D may
not be clinically effective in preventing falls in the elderly
[10], while two trials that used 800 IU of vitamin D per day
plus calcium reduced the risk of falling [6, 7]. For the two
short-term trials with 259 subjects using 800 IU of
cholecalciferol (study duration 3 to 12 months), the
corrected pooled OR was 0.65 [95% CI (0.40, 1.00)] [5].
Since then, two long-term trials confirmed fall reduction
with vitamin D supplementation [11, 12]. In one double-
blind RCT, a 3-year supplementation with cholecalciferol
700 IU plus 500 mg calcium reduced the odds of falling in
community-dwelling Boston women by 46% (OR=0.54;
95% confidence interval, 0.30–0.97) and was most pro-
nounced in less active women by 65% (OR=0.35; 95% CI,
0.15–0.81) [11]. Mean serum 25(OH)D increased to
99 nmol/l (diasorin-adjusted level) in the treatment group.
In a multicenter study of assisted living facilities and
nursing homes across Australia, vitamin D supplementation
(ergocalciferol, initially 10,000 IU given once weekly and
then 1,000 IU daily) reduced the incident rate ratio for
falling by 26% (RR=0.73, 95% confidence interval, 0.57–
0.95) [12].
Impact of adherence to treatment on fracture efficacy
with vitamin D
Since the 2005 meta-analysis [2], two large double-blind
RCTs have been published. One trial, the UK Record trial,
tested 800 IU vitamin D with or without calcium among
5,292 people aged 70 years or older who were mobile
before developing a low-trauma fracture [13]. Their
baseline mean 25(OH)D serum levels were low with
38 nmol/l [13]. The incidence of new, low-trauma fractures
did not differ significantly between participants allocated to
800 IU vitamin D per day and those who were not [HR=
1.02 (0.88–1.19)]. However, the treatment group achieved
mean 25(OH)D levels of only 62 nmol/l, which is not in
the desirable range for fracture efficacy according to the
previous meta-analysis [2]. The small increase in serum 25
(OH)D may be explained by the low adherence rate, which
was 60% at 12 months and 47% at 24 months among
persons who returned the 4-monthly questionnaire.
In the second most recently published trial, the Women’s
Health Initiative (WHI) trial, 400 IU vitamin D plus
1,000 mg calcium per day compared to placebo did not
reduce hip fracture risk in 36,282 calcium-replete postmen-
opausal women aged 50 to 79 years with a mean baseline
vitamin D intake of 360 IU per day (HR=0.88; 95% CI,
0.72 to 1.08). This is consistent with the 2005 meta-
analysis, where 400 IU vitamin D per day was not enough
to reduce fracture risk. However, if women who ceased to
adhere to the study medication were excluded in the WHI
trial, hip fracture risk was reduced by 29% (HR=0.71, 95%
CI, 0.52 to 0.97).
Adherence to treatment is an important determinant of
fracture efficacy with vitamin D supplementation. Figure 1
illustrates hip fracture efficacy by total vitamin D intake in
the treatment group considering compliance and additional
vitamin D intake (WHI women consumed a mean of
360 IU vitamin D throughout the trial [14]). The graph
suggests that efficacy increases with higher predicted actual
mean intake of vitamin D in the treatment group. Studies
that were successful in fracture reduction had an actual
mean estimated intake of more than 600 IU per day, and
associated achieved mean 25(OH)D levels were close to
75 nmol/l. Levels of 25(OH)D are expressed in DiaSorin
equivalent levels in Fig. 1 as measurements of 25-OHD
vary between assays [15], and the DiaSorin assay is widely
used.
What dose is needed to achieve adequate
25-hydroxyvitamin D levels in the management
of osteoporosis?
Studies suggest that 700 to 1,000 IU of vitamin D per day
may bring 50% of younger and older adults up to 75–
100 nmol/l [16–18]. Thus, to bring most older adults to the
desirable range of 75–100 nmol/l, vitamin D doses higher
than 700–1,000 IU would be needed. The current intake
recommendation for older persons (600 IU per day) may
bring most individuals to 50–60 nmol/l, but not to 75–
100 nmol/l [3]. According to studies in younger adults,
intakes of as high as 4,000 IU to 10,000 IU are safe [19,
20], and 4,000 IU may bring 88% of healthy young men
and women to at least 75 nmol/l [20]. Heaney and
colleagues, in a study of healthy men estimated that
1,000 IU cholecalciferol per day are needed during winter
months in Nebraska to maintain a late summer starting level
of 70 nmol/l, while baseline levels between 20–40 nmol/l
may require a daily dose of 2,200 IU vitamin D to reach
and maintain 80 nmol/l [19, 21]. These results indicate that
individuals with a lower starting level may need a higher
dose of vitamin D to achieve desirable levels, while
relatively lower doses may be sufficient in individuals
who start at higher baseline levels.
If 75 nmol/l were the minimum target level of a revised
RDA (recommended daily allowance), the new RDA
should meet the requirements of 97% of the population
[22]. Based on a dose-response calculation proposed by Dr.
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Heaney of about 1.0 nmol/(l μg day) at the lower end of the
distribution and 0.6 nmol/(l μg day) at the upper end [21], a
daily oral dose of 2,000 IU (50 mcg/day), the safe upper
intake limit as defined by the National Academy of Science
[23], may shift the NHANES III distribution so that only
about 10–15% of individuals are below 75 nmol/l. This
may result in a 35 nmol/l shift in already replete individuals
from between 75–140 nmol/l (NHANES III distribution) to
110–175 nmol/l, which are levels observed in healthy
outdoor workers (i.e., farmers: 135 nmol/l [24] and
lifeguards: 163 nmol/l [25]). Thus, 2,000 IU may be a safe
RDA even at the higher end of the normal 25(OH)D serum
level distribution, and for the lower end it may be
conservative. As a first sign of toxicity, only serum 25
(OH)D levels of above 220 nmol/l have been associated
with hypercalcemia [26, 27]. Thus, the upper end of the
acceptable range should probably not exceed 200 nmol/l
(80 ng/ml).
Due to seasonal fluctuations of 25(OH)D levels [28],
some individuals may be in the desirable range during the
summer months. However, these levels will not be
sustained during the winter months, even in sunny latitudes
[29, 30]. Thus, winter supplementation with vitamin D is
needed even after a sunny summer. Furthermore, several
studies suggest that many older persons will not achieve
optimal serum 25(OH)D levels during the summer months,
suggesting that vitamin D supplementation should be
independent of the season in older persons [30–32].
Treatment strategies to overcome low compliance
to vitamin D
Adherence may be increased by intermittent higher doses
of vitamin D applied by intra-muscular injection or
orally. Unfortunately, no classically randomized clinical
trial with intramuscular 300,000 IU ergocalciferol was
successful in fracture reduction. The serum concentra-
tions achieved with annual injections of 300,000 IU
ergocalciferol are similar to those produced by daily oral
400 IU cholecalciferol and do not ensure that individuals
reach desirable 25(OH)D levels of 75 nmol/l. Based on
two fracture trials with this regimen in older individuals,
25(OH)D levels rose by about 20 to 30 nmol/l to between
45 and 65 nmol/l [33–35], and fracture reduction was
seen in one of the two trials [33]. But since the authors of
Fig. 1 Hip fracture efficacy by total estimated vitamin D intake (all
trials used oral cholecalciferol) considering adherence to treatment.
Compliance in the different trials was reported as follows: Lips (400 IU
per day)=85% [36], Record (800 IU per day)=47% [13], WHI* intent-
to-treat analysis (400 IU per day plus additional reported mean vitamin
D intake of 360 IU)=59% [14], Trivedi (100,000 IU every 4 months
equals 820 IU per day)=76% (&includes hip plus forearm fractures)
[38], Chapuy (800 IU per day)=84% [57], WHI**-compliant women
(400 IU per day plus additional reported mean vitamin D intake of
360 IU)=100% [14]. In most studies, being compliant was defined as
taking 80% or more of the study medication. The x-axis gives the
DiaSorin equivalent 25(OH)D levels in nmol/l achieved in the
treatment arm of the trials. #For the Record trial a HPLC method has
been used for 25(OH)D measurement with an unknown DiaSorin
equivalent value. In the WHI trial, 25(OH)D levels have not been
measured at follow-up in the study population (n.a. = not available)
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the smaller positive trial did not use a classic randomiza-
tion technique, the observed fracture reduction in 899
older individuals with annual 150,000 to 300,000 IU
ergocalciferol has been questioned [33], especially as a
recent larger trial with 9,440 community-dwelling older
individuals aged 75 to 100 years that used classic
randomization did not document fracture or fall reduction
with annual intra-muscular 300,000 IU ergocalciferol.
Thus, intra-muscular vitamin D may increase 25(OH)D,
similarly to what has been observed with oral daily 400 IU
cholecalciferol [36, 37], but is, like oral daily 400 IU
cholecalciferol, insufficient to achieve desirable 25(OH)D
levels of at least 75 nmol/l for anti-fall and anti-fracture
efficacy [2, 5, 35–37].
Another high-dose strategy tested in a large double-blind
RCT of 2,686 older individuals aged 65–85 years living in
the general community compared an oral dose of
100,000 IU cholecalciferol every 4 months to a placebo
[38]. In this trial, hip plus forearm fractures were reduced
significantly by 23% [RR=0.67; 95% CI (0.46, 0.99)] over
5 years, while mean serum 25(OH)D levels increased to the
desirable range in the treatment group (74 nmol/l). The
authors, as documented in a preceding study among 189
healthy free-living men and women aged 63–76 years,
found this regimen to be safe [39].
Although not tested for fracture prevention and based on
limited data, another approach to improve adherence to
vitamin D may be artificial UV-B radiation. Older individ-
uals avoid sunshine exposure, and the production of
vitamin D3 in the skin is four times lower plus contains
50% less 7-dehydrocholesterol, which is the substrate of
photoconversion to previtamin D, if compared to young
individuals [40, 41]. Still, Chel and colleagues found that
UV-B radiation at half the minimal erythemal dose of the
lower back (1,000 cm2) for a few minutes three times a
week over 12 weeks increased serum 25(OH)D concen-
trations in institutionalized older individuals similar to a
daily oral dose of 400 IU cholecalciferol [42]. Both groups
achieved mean serum 25(OH)D concentrations of about
60 nmol/l at the 12-week follow-up. Safety and efficacy
data over longer periods of time are needed for this
approach [43].
In clinical practice with the target of vitamin D adequacy
in mind, a combination of the annual intra-muscular
injection with 300,000 IU vitamin D plus a daily
multivitamin containing 400 IU vitamin D and/or an oral
calcium plus vitamin D combination may be a possibility.
The annual intra-muscular injection of 300,000 IU vitamin
D is not enough to reach vitamin D desirable 25(OH)D
levels, but may serve as a basis to build on. Table 1
summarizes treatment options with vitamin D and their
potential to reach 25(OH)D adequacy for fall and fracture
reduction.
Chronic kidney disease
In a large population-based survey in the US, 11% of
individuals older than 65 years without hypertension or
diabetes had stage 3 or worse chronic kidney disease (GFR
<60 ml/min) [44]. According to the K/DOQI (National
Kidney Foundation, Kidney Disease Outcome Initiative)
clinical practice guidelines for bone metabolism and disease
in chronic kidney disease, supplementation with vitamin D
should be initiated if the serum level of 25(OH)D
concentrations is below 75 nmol/l in individuals with a
glomerular filtration rate of less than 60 ml/min (http://
www.kidney.org/professionals/kdoqi/guidelines_bone).
For chronic kidney disease stage 3 (GFR 30–59 ml/min)
or 4 (15–29 ml/min), K/DOQI recomments 50,000 IU
ergocalciferol once a week for 4 weeks and then 50,000 IU
once per month in individuals with serum 25(OH)D levels
of 12–37 nmol/l. In those with serum concentrations
between 40–75 nmol/l, the recommendation is 50,000 IU
once per month. Active vitamin D metabolites are not
recommended for the treatment of vitamin D inadequacy in
mild to moderate chronic kidney disease. However, there is
no evidence that in patients with GFR below 20 ml/min or
on dialysis, vitamin D supplementation alone will increase
1,25-dihydroxyvitamin D levels or lower PTH.
Importance of additional calcium supplementation
As a large part of older individuals are at risk for vitamin D
and calcium deficiency [4, 45], there is a good rationale to
supplement calcium in combination with vitamin D for
non-vertebral fracture prevention. This is supported by the
most recent meta-analysis by Boonen and colleagues,
including the latest fracture trial data (WHI [14], Record
Table 1 Different vitamin D regimens, achieved 25(OH)D serum
concentrations, and fall and fracture efficacy
Application Expected mean
25(OH)D serum
concentrations
Anti-fall
efficacy
Anti-
fracture
efficacy
Oral daily 400 IU
cholecalciferol [36, 37]
60 to 65 nmol/l No No
Oral daily 700–800 IU
cholecalciferol [2]
74 to 110 nmol/l Yes Yes
Oral 100,000 IU
cholecalciferol every
4 months [38]
74 nmol/l ? Yes
Annual 300,000 IU
ergocalciferol [33, 35]
45 to 65 nmol/l No No*
The data presented in the table assume adherence to treatment of at
least 80%.
*As discussed in the text, two trials have been performed with
conflicting results
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[13], Porthouse [46]) up to March 2006 as presented at the
ASBMR meeting in Philadelphia, September 2006 [47]. The
results of the meta-analysis indicate that based on four RCTs
(9,083 individuals), the pooled RR of hip fracture for
vitamin D supplementation alone was 1.10 [95% confidence
intervals (CI), 0.89 to 1.36]. On the other hand, for six RCTs
(45,509 individuals) of vitamin D supplementation with
calcium supplementation, the pooled RR for hip fracture was
0.82 (95% CI, 0.71 to 0.94). Using a similar database, a
Cochrane Review published in 2005 supported the benefits
of combined vitamin D plus calcium [48]. The authors found
that trials using vitamin D plus calcium compared to placebo
or no treatment resulted in a statistically significant reduction
in the incidence of both hip (seven RCTs, 10,376 individ-
uals, pooled RR=0.81; 95% CI 0.68 to 0.96) and new non-
vertebral fracture (seven RCTs, 10,376 individuals, pooled
RR=0.87; 95% CI 0.78 to 0.97). The different trials used
calcium supplementations between 500 to 1,200 mg per day
in combination with vitamin D.
There are limited data about the optimal combination of
vitamin D and calcium. Some evidence, however, suggests
that calcium absorption increases with higher 25-(OH)D
levels and may plateau at 80 nmol/l as described by Heaney
and colleagues [49]. Similarly, Steingrimsdottir and col-
leagues showed that serum PTH levels in older individuals
were lowest with a serum 25-hydroxyvitamin D level of
more than 18 ng/ml, independent of calcium intake [50].
Furthermore, in a large population-based survey, hip bone
density increased with higher 25-hydroxyvitamin D levels
in both younger (age 20–49 years) and older (age 50+)
adults, independent of their calcium intake [3]. These
observational data suggest that the benefits of vitamin D
on bone may need a certain calcium intake threshold, but
benefits given a certain calcium threshold are primarily
driven by vitamin D. Findings from one large RCT by
Trivedi and colleagues suggest that non-vertebral fracture
prevention in ambulatory older individuals may be
achieved with a daily intake of about 820 IU vitamin D
(100,000 IU every 4 months) alone, provided a mean
calcium intake of at least 740 mg per day [38]. However, as
mean baseline calcium intakes in the general population
aged ≥50 years are about 763 mg/day in men and 558
mg/day in women, there is a large part of the population
with intakes below 740 mg per day [45].
Summary
The available evidence suggests that the dose of vitamin D
in the management of osteoporosis targeting fall and
fracture prevention should be no less than 700–800 IU
per day. Based on the illustration of hip fracture efficacy by
vitamin D treatment and adherence to treatment (Fig. 1),
total estimated daily intakes below 600 IU vitamin D per
day are insufficient for fall or fracture prevention. Also,
desirable serum 25(OH)D concentrations of 75 nmol/l are
not achieved.
Adherence may be improved with higher intermittent
doses of vitamin D, such as oral 100,000 IU cholecalciferol
every 4 months, which reduced fractures significantly in
community-dwelling older individuals and shifted their
mean 25(OH)D concentrations to the desirable range.
Alternatively, the annual intra-muscular injection of
300,000 IU ergocalciferol or cholecalciferol may provide
the equivalent of an oral daily dose of 400 IU cholecalcif-
erol, which is not sufficient for fall or fracture prevention,
but may help individuals with limited adherence to increase
their total daily vitamin D supply beyond 600 IU per day.
Based on data from a recent worldwide survey among
postmenopausal women diagnosed with osteoporosis, about
64% were below the desirable level of 75 nmol/l, indicating
that public health efforts need further support [51].
Furthermore, a national US survey shows that only 31%
of adult Caucasians between 20 and 49 years of age and
less than 9% of older Caucasians, and an even smaller
fraction of the Mexican-American and African-American
adults have serum 25(OH)D levels of 90 nmol/l or more
[3], and only about one third reach 75 nmol/l [52]. Most
vulnerable to low vitamin D levels are older individuals
[30, 53], individuals living in northern latitudes with
prolonged winters [28, 54], obese individuals [55], and
African Americans of all ages [3, 52, 56].
Thus, a large majority of the population could benefit
from vitamin D supplementation. Hence, it would seem
prudent to ensure that all individuals aged 65 years and
older take at least 700–800 IU vitamin D per day [2], and a
combination with calcium as suggested by a recent meta-
analysis may be important at vitamin D intakes between
400–800 IU [47]. Future research should address the safety
and efficacy of higher daily doses of vitamin D in older
individuals. Especially 2,000 IU cholecalciferol per day
appears to have an appealing potential to bring the large
majority of older individuals into the desirable range of 25
(OH)D where optimal fall and fracture prevention is
expected. As calcium absorption is improved with higher
serum 25(OH)D levels [49, 50], these studies may also
evaluate whether current calcium intake recommendations
with higher doses of vitamin D beyond 2,000 IU are safe or
require downward adjustment [49]. If dietary calcium is a
threshold nutrient, as suggested by Dr. Heaney [21], then
that threshold for optimal calcium absorption may be at a
lower calcium intake when vitamin D nutrition is higher.
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